{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:40:52Z","timestamp":1772271652556,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"DOI":"10.7759\/cureus.83309","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T13:09:43Z","timestamp":1746104983000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Losartan on Portal Hypertension and Liver Cirrhosis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Deepti","family":"Avasthi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Zerilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taimoor","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniyal","family":"Ishtiaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salil","family":"Avasthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1060073","article-title":"Pathophysiology and management of liver cirrhosis: From portal hypertension to acute-on-chronic liver failure","volume":"10","author":"Jagdish RK","year":"2023","unstructured":"Jagdish RK, Roy A, Kumar K, et al.. Pathophysiology and management of liver cirrhosis: From portal hypertension to acute-on-chronic liver failure. Front Med (Lausanne). 2023, 10:1060073. 10.3389\/fmed.2023.1060073","journal-title":"Front Med (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i14.4460","article-title":"Correlation of pressure gradient in three hepatic veins with portal pressure gradient","volume":"10","author":"Wang HY","year":"2022","unstructured":"Wang HY, Song QK, Yue ZD, et al.. Correlation of pressure gradient in three hepatic veins with portal pressure gradient. World J Clin Cases. 2022, 10:4460-9. 10.12998\/wjcc.v10.i14.4460","journal-title":"World J Clin Cases"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.210","article-title":"Cirrhotic cardiomyopathy: Pathogenesis and clinical relevance","volume":"11","author":"Wiese S","year":"2014","unstructured":"Wiese S, Hove JD, Bendtsen F, M\u00f8ller S. Cirrhotic cardiomyopathy: Pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol. 2014, 11:177-86. 10.1038\/nrgastro.2013.210","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i40.6111","article-title":"Cirrhotic portal hypertension: From pathophysiology to novel therapeutics","volume":"26","author":"Gunarathne LS","year":"2020","unstructured":"Gunarathne LS, Rajapaksha H, Shackel N, Angus PW, Herath CB. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World J Gastroenterol. 2020, 26:6111-40. 10.3748\/wjg.v26.i40.6111","journal-title":"World J Gastroenterol"},{"key":"ref5","article-title":"Effects of propranolol on portal hemodynamics in patients with chronic liver disease","volume":"80","author":"Ohnishi K","year":"1985","unstructured":"Ohnishi K, Nakayama T, Saito M, et al.. Effects of propranolol on portal hemodynamics in patients with chronic liver disease. Am J Gastroenterol. 1985, 80:132-5.","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(87)80012-0","article-title":"Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis","volume":"4","author":"Mastai R","year":"1987","unstructured":"Mastai R, Bosch J, Navasa M, Kravetz D, Bruix J, Viola C, Rod\u00e9s J. Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. J Hepatol. 1987, 4:71-9. 10.1016\/s0168-8278(87)80012-0","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.05.050","article-title":"Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: A meta-analysis","volume":"18","author":"Turco L","year":"2020","unstructured":"Turco L, Villanueva C, La Mura V, et al.. Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: A meta-analysis. Clin Gastroenterol Hepatol. 2020, 18:313-27.e6. 10.1016\/j.cgh.2019.05.050","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50133","article-title":"Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis","volume":"37","author":"Abraldes JG","year":"2003","unstructured":"Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rod\u00e9s J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003, 37:902-8. 10.1053\/jhep.2003.50133","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00438-7","article-title":"The pathophysiology and therapeutic options for cirrhotic portal hypertension","volume":"9","author":"Guix\u00e9-Muntet S","year":"2024","unstructured":"Guix\u00e9-Muntet S, Quesada-V\u00e1zquez S, Gracia-Sancho J. The pathophysiology and therapeutic options for cirrhotic portal hypertension. Lancet Gastroenterol Hepatol. 2024, 9:646-63. 10.1016\/S2468-1253(23)00438-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040702","article-title":"Update on new aspects of the renin-angiotensin system in hepatic fibrosis and portal hypertension: Implications for novel therapeutic options","volume":"10","author":"Rajapaksha IG","year":"2021","unstructured":"Rajapaksha IG, Gunarathne LS, Angus PW, Herath CB. Update on new aspects of the renin-angiotensin system in hepatic fibrosis and portal hypertension: Implications for novel therapeutic options. J Clin Med. 2021, 10:702. 10.3390\/jcm10040702","journal-title":"J Clin Med"},{"key":"ref11","article-title":"Pathophysiology of portal hypertension","author":"Iwakiri Y","year":"2020","unstructured":"Iwakiri Y, Groszmann RJ. Pathophysiology of portal hypertension. The Liver: Biology and Pathobiology. 2020. 659-669."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.46542\/pe.2023.236.350423","article-title":"Pharmacist interventions to improve hypertension management: From trials to implementation","volume":"23","author":"Gastens V","year":"2023","unstructured":"Gastens V, Tancredi S, Kiszio B, et al.. Pharmacist interventions to improve hypertension management: From trials to implementation. Pharm Educ. 2023, 23:364. 10.46542\/pe.2023.236.350423","journal-title":"Pharm Educ"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-201410002-00598","article-title":"A meta-analysis and systematic review comparing losartan and propranolol in lowering portal hypertension in cirrhosis","volume":"109","author":"Sayyar M","year":"2014","unstructured":"Sayyar M, Sawas T, Cho W. A meta-analysis and systematic review comparing losartan and propranolol in lowering portal hypertension in cirrhosis. Am J Gastroenterol . 2014, 109:S175.","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: A comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley AM","year":"2014","unstructured":"Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: A comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014, 14:579. 10.1186\/s12913-014-0579-0","journal-title":"BMC Health Serv Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1090","article-title":"Assessing baseline imbalance in randomised trials: Implications for the Cochrane risk of bias tool","volume":"5","author":"Corbett MS","year":"2014","unstructured":"Corbett MS, Higgins JP, Woolacott NF. Assessing baseline imbalance in randomised trials: Implications for the Cochrane risk of bias tool. Res Synth Methods. 2014, 5:79-85. 10.1002\/jrsm.1090","journal-title":"Res Synth Methods"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41168.x","article-title":"A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension","volume":"100","author":"Sookoian S","year":"2005","unstructured":"Sookoian S, Casta\u00f1o G, Garc\u00eda SI, Viudez P, Gonz\u00e1lez C, Pirola CJ. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. Am J Gastroenterol. 2005, 100:636-42. 10.1111\/j.1572-0241.2005.41168.x","journal-title":"Am J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04051.x","article-title":"Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis","volume":"99","author":"Tripathi D","year":"2004","unstructured":"Tripathi D, Therapondos G, Lui HF, Johnston N, Webb DJ, Hayes PC. Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am J Gastroenterol. 2004, 99:390-4. 10.1111\/j.1572-0241.2004.04051.x","journal-title":"Am J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21309","article-title":"The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis","volume":"44","author":"Therapondos G","year":"2006","unstructured":"Therapondos G, Hol L, Benjaminov F, Wong F. The effect of single oral low-dose losartan on posture-related sodium handling in post-TIPS ascites-free cirrhosis. Hepatology. 2006, 44:640-9. 10.1002\/hep.21309","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i48.7560","article-title":"Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study","volume":"11","author":"Sookoian S","year":"2005","unstructured":"Sookoian S, Fern\u00e1ndez MA, Casta\u00f1o G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study. World J Gastroenterol. 2005, 11:7560-3. 10.3748\/wjg.v11.i48.7560","journal-title":"World J Gastroenterol"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1016\/S1665-2681(19)32156-8","article-title":"A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients","volume":"2","author":"Casta\u00f1o G","year":"2003","unstructured":"Casta\u00f1o G, Viudez P, Riccitelli M, Sookoian S. A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients. Ann Hepatol. 2003, 2:36-40.","journal-title":"Ann Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07497.x","article-title":"Portal pressure response to losartan compared with propranolol in patients with cirrhosis","volume":"98","author":"De BK","year":"2003","unstructured":"De BK, Bandyopadhyay K, Das TK, et al.. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol. 2003, 98:1371-6. 10.1111\/j.1572-0241.2003.07497.x","journal-title":"Am J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290203","article-title":"Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis","volume":"29","author":"Schneider AW","year":"1999","unstructured":"Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999, 29:334-9. 10.1002\/hep.510290203","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12025","article-title":"Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease","volume":"14","author":"Agasti AK","year":"2013","unstructured":"Agasti AK, Mahajan AU, Phadke AY, Nathani PJ, Sawant P. Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease. J Dig Dis. 2013, 14:266-71. 10.1111\/1751-2980.12025","journal-title":"J Dig Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.26288","article-title":"Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis","volume":"121","author":"Gonz\u00e1lez-Abraldes J","year":"2001","unstructured":"Gonz\u00e1lez-Abraldes J, Albillos A, Ba\u00f1ares R, et al.. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology. 2001, 121:382-8. 10.1053\/gast.2001.26288","journal-title":"Gastroenterology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.33375","article-title":"Discussion on randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis","volume":"122","author":"Casta\u00f1o G","year":"2002","unstructured":"Casta\u00f1o G, Viudez P, Frider B, Sookoian S. Discussion on randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology. 2002, 122:1544-5. 10.1053\/gast.2002.33375","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(99)70472-5","article-title":"Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: A caution","volume":"117","author":"Garc\u00eda-Tsao G","year":"1999","unstructured":"Garc\u00eda-Tsao G. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: A caution. Gastroenterology. 1999, 117:740-2. 10.1016\/s0016-5085(99)70472-5","journal-title":"Gastroenterology"},{"key":"ref28","article-title":"Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy","volume":"53","author":"Wagatsuma Y","year":"2006","unstructured":"Wagatsuma Y, Naritaka Y, Shimakawa T, et al.. Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy. Hepatogastroenterology. 2006, 53:171-4.","journal-title":"Hepatogastroenterology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/17439760.2016.1262613","article-title":"Thematic analysis","volume":"12","author":"Clarke V","year":"2016","unstructured":"Clarke V, Braun V. Thematic analysis. J Posit Psychol. 2016, 12:297-8. 10.1080\/17439760.2016.1262613","journal-title":"J Posit Psychol"},{"key":"ref30","unstructured":"Grade Approach. Accessed. April 15, 2025: https:\/\/training.cochrane.org\/grade-approach."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-7061(97)00491-3","article-title":"Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension","volume":"11","author":"Kassler-Taub K","year":"1998","unstructured":"Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens. 1998, 11:445-53. 10.1016\/s0895-7061(97)00491-3","journal-title":"Am J Hypertens"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00238.2021","article-title":"Angiotensin receptor blocker alleviates liver fibrosis by altering the mechanotransduction properties of hepatic stellate cells","volume":"322","author":"Huang Z","year":"2022","unstructured":"Huang Z, Khalifa MO, Li P, Huang Y, Gu W, Li TS. Angiotensin receptor blocker alleviates liver fibrosis by altering the mechanotransduction properties of hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2022, 322:G446-56. 10.1152\/ajpgi.00238.2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100316","article-title":"Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy","volume":"3","author":"Iwakiri Y","year":"2021","unstructured":"Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep. 2021, 3:100316. 10.1016\/j.jhepr.2021.100316","journal-title":"JHEP Rep"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.32350\/cto.32.05","article-title":"Effect of CYP2C9 rs2860905 polymorphism on the efficacy of losartan in Pakistani hypertensive patients","volume":"3","author":"Haider QUA","year":"2023","unstructured":"Haider QUA, Saeed H, Ikram W, Ikram U, Hussain M. Effect of CYP2C9 rs2860905 polymorphism on the efficacy of losartan in Pakistani hypertensive patients. Curr Trends OMICS. 2023, 3:64-77. 10.32350\/cto.32.05","journal-title":"Curr Trends OMICS"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115807","article-title":"The renin-angiotensin system in liver disease","volume":"25","author":"McGrath MS","year":"2024","unstructured":"McGrath MS, Wentworth BJ. The renin-angiotensin system in liver disease. Int J Mol Sci. 2024, 25:5807. 10.3390\/ijms25115807","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81959-1","article-title":"Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease","volume":"11","author":"Kim KM","year":"2021","unstructured":"Kim KM, Roh JH, Lee S, Yoon JH. Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease. Sci Rep. 2021, 11:2884. 10.1038\/s41598-021-81959-1","journal-title":"Sci Rep"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.07.009","article-title":"Association of renin-angiotensin system inhibition with liver-related events and mortality in compensated cirrhosis","volume":"22","author":"Elhence H","year":"2024","unstructured":"Elhence H, Dodge JL, Lee BP. Association of renin-angiotensin system inhibition with liver-related events and mortality in compensated cirrhosis. Clin Gastroenterol Hepatol. 2024, 22:315-323.e17. 10.1016\/j.cgh.2023.07.009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.03.013","article-title":"Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis","volume":"53","author":"Tandon P","year":"2010","unstructured":"Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. J Hepatol. 2010, 53:273-82. 10.1016\/j.jhep.2010.03.013","journal-title":"J Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/337687-impact-of-losartan-on-portal-hypertension-and-liver-cirrhosis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T13:09:45Z","timestamp":1746104985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/337687-impact-of-losartan-on-portal-hypertension-and-liver-cirrhosis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.83309","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.25.24314392","asserted-by":"object"}]},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}